Shopping Cart 0
Cart Subtotal
USD 0

Ablynx NV (ABLX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Ablynx NV (Ablynx) is a biopharmaceutical company that focuses on developing Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. Nanobodies are a novel class of antibody-derived therapeutic proteins which possess structural and functional properties of naturally-occurring heavy chain only antibodies. It has advantages of conventional antibodies along with the key features of small molecule drugs. Ablynx develops Nanobodies to treat serious human diseases including acquired thrombotic thrombocytopenic purpura (aTTp), psoriasis, bone disorders, cancer and pulmonary diseases. The company has ongoing research collaborations and significant partnerships with key pharmaceutical companies including Merck, Boehringer Ingelheim and Novartis. Ablynx is headquartered in Ghent, Belgium.

Ablynx NV (ABLX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Ablynx NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Ablynx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Ablynx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Ablynx NV, Medical Devices Deals, 2012 to YTD 2018 11

Ablynx NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Ablynx NV, Pharmaceuticals & Healthcare, Deal Details 14

Private Equity 14

BVF Partners Acquires Additional 1.74% Stake In Ablynx From Sofinnova 14

Partnerships 15

Ablynx Exercises Option for Licensing Agreement with Vectura 15

Ablynx Enters into Research Agreement with Genzyme 16

Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 17

Taiwan Liposome and Ablynx Enter into Research Agreement 18

Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 19

Licensing Agreements 20

Sanofi Signs Licensing Agreement with Ablynx 20

Novo Nordisk Enters into Licensing Agreement with Ablynx 21

Taisho Pharma Enters into Licensing Agreement with Ablynx 22

Ablynx Enters into Licensing Agreement with Eddingpharm for Anti-TNFa Nanobody 23

Merck Expands Licensing Agreement with Ablynx 24

Ablynx Enters Into Licensing Agreement With Eddingpharm 26

Equity Offering 28

Ablynx Raises USD2.3 Million in Private Placement of Shares up on Exercise of Warrants 28

Ablynx Raises USD1 Million in Private Placement of Shares up on Exercise of Warrants 29

Ablynx Raises USD2 Million in Private Placement of Shares up on Exercise of Warrants 30

Ablynx Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADS for USD230 Million 31

Ablynx Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 33

Ablynx Amends Private Placement of Shares 34

Ablynx Raises USD1.05 Million Through Exercise of Warrants 36

Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 37

Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 38

Ablynx Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 39

Ablynx Raises USD82.6 Million in Private Placement of Shares 40

Ablynx Raises USD0.05 Million in Private Placement of Shares upon Exercise of Warrants 42

Ablynx Raises USD1.4 Million upon Exercise of Warrants 43

Ablynx Raises USD57 Million in Private Placement of Shares 44

Ablynx Completes Private Placement Of Shares For USD 1.2 Million Upon Exercise Of Warrants 46

Ablynx Completes Private Placement Of Shares For USD 41 Million 47

Debt Offering 49

Ablynx Raises USD112 Million in Private Placement of 3.25% Bonds Due 2020 49

Acquisition 50

Sanofi Acquires Ablynx for USD4.85 Billion 50

Sofinnova Divests Its Stake In Ablynx For USD 29.4 Million 52

Gimv And Biotech Fonds Vlaanderen Sell Remaining Stake In Ablynx 53

Gimv And Biotech Fonds Vlaanderen Sell Stake In Ablynx 54

Ablynx NV-Key Competitors 55

Ablynx NV-Key Employees 56

Ablynx NV-Locations And Subsidiaries 57

Head Office 57

Other Locations & Subsidiaries 57

Recent Developments 58

Financial Announcements 58

Feb 22, 2018: ABLYNX ANNOUNCES 2017 FULL YEAR RESULTS 58

Nov 16, 2017: Ablynx Announces Results For The First Nine Months Of 2017 And A Year-To-Date Business Update 61

Aug 24, 2017: Ablynx Announces 2017 Half Year Results and Year-to-date Business Update 63

May 11, 2017: Ablynx Reports Financial Results for the First Three Months Of 2017 and a Year-To-Date Business Update 66

Feb 23, 2017: Ablynx Announces 2016 Full Year Results 68

Corporate Communications 69

Feb 07, 2018: Ablynx Announces Resignation of Dr Bo Jesper Hansen From the Board of Directors 69

Jan 24, 2018: Ablynx Names Dr Robert Friesen as Chief Scientific Officer 70

Jan 08, 2018: Ablynx Announces Board Changes 71

Jul 17, 2017: Ablynx Proposes Appointment of Mrs Hilde Windels as a New Independent Director 72

Jun 13, 2017: Ablynx Appoints Markus Ewert As Chief Business Officer 73

Mar 07, 2017: Merck reports positive data from Phase Ib trial of M1095 in psoriasis patients 74

Clinical Trials 75

Jan 11, 2017: Ablynx Initiates Phase IIb Respire Study of its Inhaled Anti-RSV Nanobody, Alx-0171, For Treatment of RSV Infections In Hospitalised Infants 75

Appendix 77

Methodology 77

About GlobalData 77

Contact Us 77

Disclaimer 77


List Of Figure

List of Figures

Ablynx NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Ablynx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Ablynx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Ablynx NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Ablynx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Ablynx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Ablynx NV, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Ablynx NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Ablynx NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Ablynx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Ablynx NV, Deals By Therapy Area, 2012 to YTD 2018 10

Ablynx NV, Medical Devices Deals, 2012 to YTD 2018 11

Ablynx NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

BVF Partners Acquires Additional 1.74% Stake In Ablynx From Sofinnova 14

Ablynx Exercises Option for Licensing Agreement with Vectura 15

Ablynx Enters into Research Agreement with Genzyme 16

Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 17

Taiwan Liposome and Ablynx Enter into Research Agreement 18

Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 19

Sanofi Signs Licensing Agreement with Ablynx 20

Novo Nordisk Enters into Licensing Agreement with Ablynx 21

Taisho Pharma Enters into Licensing Agreement with Ablynx 22

Ablynx Enters into Licensing Agreement with Eddingpharm for Anti-TNFa Nanobody 23

Merck Expands Licensing Agreement with Ablynx 24

Ablynx Enters Into Licensing Agreement With Eddingpharm 26

Ablynx Raises USD2.3 Million in Private Placement of Shares up on Exercise of Warrants 28

Ablynx Raises USD1 Million in Private Placement of Shares up on Exercise of Warrants 29

Ablynx Raises USD2 Million in Private Placement of Shares up on Exercise of Warrants 30

Ablynx Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADS for USD230 Million 31

Ablynx Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 33

Ablynx Amends Private Placement of Shares 34

Ablynx Raises USD1.05 Million Through Exercise of Warrants 36

Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 37

Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 38

Ablynx Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 39

Ablynx Raises USD82.6 Million in Private Placement of Shares 40

Ablynx Raises USD0.05 Million in Private Placement of Shares upon Exercise of Warrants 42

Ablynx Raises USD1.4 Million upon Exercise of Warrants 43

Ablynx Raises USD57 Million in Private Placement of Shares 44

Ablynx Completes Private Placement Of Shares For USD 1.2 Million Upon Exercise Of Warrants 46

Ablynx Completes Private Placement Of Shares For USD 41 Million 47

Ablynx Raises USD112 Million in Private Placement of 3.25% Bonds Due 2020 49

Sanofi Acquires Ablynx for USD4.85 Billion 50

Sofinnova Divests Its Stake In Ablynx For USD 29.4 Million 52

Gimv And Biotech Fonds Vlaanderen Sell Remaining Stake In Ablynx 53

Gimv And Biotech Fonds Vlaanderen Sell Stake In Ablynx 54

Ablynx NV, Key Competitors 55

Ablynx NV, Key Employees 56

Ablynx NV, Subsidiaries 57

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Ablynx NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Ablynx NV (Ablynx) is a biopharmaceutical company that focuses on developing Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. Nanobodies are a novel class of antibody-derived therapeutic proteins which possess structural and functional properties of naturally-occurring heavy chain only antibodies. It has advantages of conventional antibodies along with the key features of small molecule drugs. Ablynx develops Nanobodies to treat serious human diseases including acquired thrombotic thrombocytopenic purpura (aTTp), psoriasis, bone disorders, cancer and pulmonary diseases. The company has ongoing research collaborations and significant partnerships with key pharmaceutical companies including Merck, Boehringer Ingelheim and Novartis. Ablynx is headquartered in Ghent, Belgium.

Ablynx NV (ABLX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Ablynx NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Ablynx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Ablynx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Ablynx NV, Medical Devices Deals, 2012 to YTD 2018 11

Ablynx NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Ablynx NV, Pharmaceuticals & Healthcare, Deal Details 14

Private Equity 14

BVF Partners Acquires Additional 1.74% Stake In Ablynx From Sofinnova 14

Partnerships 15

Ablynx Exercises Option for Licensing Agreement with Vectura 15

Ablynx Enters into Research Agreement with Genzyme 16

Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 17

Taiwan Liposome and Ablynx Enter into Research Agreement 18

Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 19

Licensing Agreements 20

Sanofi Signs Licensing Agreement with Ablynx 20

Novo Nordisk Enters into Licensing Agreement with Ablynx 21

Taisho Pharma Enters into Licensing Agreement with Ablynx 22

Ablynx Enters into Licensing Agreement with Eddingpharm for Anti-TNFa Nanobody 23

Merck Expands Licensing Agreement with Ablynx 24

Ablynx Enters Into Licensing Agreement With Eddingpharm 26

Equity Offering 28

Ablynx Raises USD2.3 Million in Private Placement of Shares up on Exercise of Warrants 28

Ablynx Raises USD1 Million in Private Placement of Shares up on Exercise of Warrants 29

Ablynx Raises USD2 Million in Private Placement of Shares up on Exercise of Warrants 30

Ablynx Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADS for USD230 Million 31

Ablynx Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 33

Ablynx Amends Private Placement of Shares 34

Ablynx Raises USD1.05 Million Through Exercise of Warrants 36

Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 37

Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 38

Ablynx Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 39

Ablynx Raises USD82.6 Million in Private Placement of Shares 40

Ablynx Raises USD0.05 Million in Private Placement of Shares upon Exercise of Warrants 42

Ablynx Raises USD1.4 Million upon Exercise of Warrants 43

Ablynx Raises USD57 Million in Private Placement of Shares 44

Ablynx Completes Private Placement Of Shares For USD 1.2 Million Upon Exercise Of Warrants 46

Ablynx Completes Private Placement Of Shares For USD 41 Million 47

Debt Offering 49

Ablynx Raises USD112 Million in Private Placement of 3.25% Bonds Due 2020 49

Acquisition 50

Sanofi Acquires Ablynx for USD4.85 Billion 50

Sofinnova Divests Its Stake In Ablynx For USD 29.4 Million 52

Gimv And Biotech Fonds Vlaanderen Sell Remaining Stake In Ablynx 53

Gimv And Biotech Fonds Vlaanderen Sell Stake In Ablynx 54

Ablynx NV-Key Competitors 55

Ablynx NV-Key Employees 56

Ablynx NV-Locations And Subsidiaries 57

Head Office 57

Other Locations & Subsidiaries 57

Recent Developments 58

Financial Announcements 58

Feb 22, 2018: ABLYNX ANNOUNCES 2017 FULL YEAR RESULTS 58

Nov 16, 2017: Ablynx Announces Results For The First Nine Months Of 2017 And A Year-To-Date Business Update 61

Aug 24, 2017: Ablynx Announces 2017 Half Year Results and Year-to-date Business Update 63

May 11, 2017: Ablynx Reports Financial Results for the First Three Months Of 2017 and a Year-To-Date Business Update 66

Feb 23, 2017: Ablynx Announces 2016 Full Year Results 68

Corporate Communications 69

Feb 07, 2018: Ablynx Announces Resignation of Dr Bo Jesper Hansen From the Board of Directors 69

Jan 24, 2018: Ablynx Names Dr Robert Friesen as Chief Scientific Officer 70

Jan 08, 2018: Ablynx Announces Board Changes 71

Jul 17, 2017: Ablynx Proposes Appointment of Mrs Hilde Windels as a New Independent Director 72

Jun 13, 2017: Ablynx Appoints Markus Ewert As Chief Business Officer 73

Mar 07, 2017: Merck reports positive data from Phase Ib trial of M1095 in psoriasis patients 74

Clinical Trials 75

Jan 11, 2017: Ablynx Initiates Phase IIb Respire Study of its Inhaled Anti-RSV Nanobody, Alx-0171, For Treatment of RSV Infections In Hospitalised Infants 75

Appendix 77

Methodology 77

About GlobalData 77

Contact Us 77

Disclaimer 77


List Of Figure

List of Figures

Ablynx NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Ablynx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Ablynx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Ablynx NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Ablynx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Ablynx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Ablynx NV, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Ablynx NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Ablynx NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Ablynx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Ablynx NV, Deals By Therapy Area, 2012 to YTD 2018 10

Ablynx NV, Medical Devices Deals, 2012 to YTD 2018 11

Ablynx NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

BVF Partners Acquires Additional 1.74% Stake In Ablynx From Sofinnova 14

Ablynx Exercises Option for Licensing Agreement with Vectura 15

Ablynx Enters into Research Agreement with Genzyme 16

Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 17

Taiwan Liposome and Ablynx Enter into Research Agreement 18

Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 19

Sanofi Signs Licensing Agreement with Ablynx 20

Novo Nordisk Enters into Licensing Agreement with Ablynx 21

Taisho Pharma Enters into Licensing Agreement with Ablynx 22

Ablynx Enters into Licensing Agreement with Eddingpharm for Anti-TNFa Nanobody 23

Merck Expands Licensing Agreement with Ablynx 24

Ablynx Enters Into Licensing Agreement With Eddingpharm 26

Ablynx Raises USD2.3 Million in Private Placement of Shares up on Exercise of Warrants 28

Ablynx Raises USD1 Million in Private Placement of Shares up on Exercise of Warrants 29

Ablynx Raises USD2 Million in Private Placement of Shares up on Exercise of Warrants 30

Ablynx Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADS for USD230 Million 31

Ablynx Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 33

Ablynx Amends Private Placement of Shares 34

Ablynx Raises USD1.05 Million Through Exercise of Warrants 36

Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 37

Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 38

Ablynx Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 39

Ablynx Raises USD82.6 Million in Private Placement of Shares 40

Ablynx Raises USD0.05 Million in Private Placement of Shares upon Exercise of Warrants 42

Ablynx Raises USD1.4 Million upon Exercise of Warrants 43

Ablynx Raises USD57 Million in Private Placement of Shares 44

Ablynx Completes Private Placement Of Shares For USD 1.2 Million Upon Exercise Of Warrants 46

Ablynx Completes Private Placement Of Shares For USD 41 Million 47

Ablynx Raises USD112 Million in Private Placement of 3.25% Bonds Due 2020 49

Sanofi Acquires Ablynx for USD4.85 Billion 50

Sofinnova Divests Its Stake In Ablynx For USD 29.4 Million 52

Gimv And Biotech Fonds Vlaanderen Sell Remaining Stake In Ablynx 53

Gimv And Biotech Fonds Vlaanderen Sell Stake In Ablynx 54

Ablynx NV, Key Competitors 55

Ablynx NV, Key Employees 56

Ablynx NV, Subsidiaries 57

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Ablynx NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.